Bumrungrad Hospital Public Company Limited owns and operates hospitals in Thailand and internationally. It offers services in the areas of allergy, arrhythmia, behavioural health, breast, home, heart valve, robotic surgery, rehabilitation, spine, paediatrics, colorectal surgery, complex coronary artery intervention, comprehensive sleep, cornea transplant, dental, diagnostic, dialysis, radiology and nuclear medicine, digestive disease, ear, nose, throat, emergency, endocrinology, esperance, diabetes, expatriate liaison, eye, fertility, gastrointestinal motility, health screening, holistic wound care, horizon regional cancer, hyperbaric oxygen therapy, nephrology, neuroscience, orthopaedics, perinatal, plastic surgery, pulmonary, refractive surgery, memory, robotic scoliosis, skin, sports medicine and joint, surgery, travel medicine, urology, scientific wellness, skin and aesthetic, and women's centers. The company also operates breastfeeding, Yangon, COVID-19 recovery, IVF, hearing and balance, medical, new life healthy aging, Parkinson's disease and movement disorders, pride, surgery, and vaccine clinics and centers. In addition, it operates spine institute, heart institute, and intensive care unit; and offers nutrition services, pharmacy services, preventive genomics and integrative medicine services. Further, the company offers clinical research, hospital consulting and management, healthcare personnel development and training, healthcare referral, and digital platform services. Additionally, it is involved in the distribution of pharmaceutical and medical goods in specialized stores; development of software for healthcare services; holding of real estate assets; and manufacture and sale of vitamin supplements. Bumrungrad Hospital Public Company Limited was founded in 1975 and is based in Bangkok, Thailand.
Metrics to compare | BH_p | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBH_pPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | 17.2x | −0.4x | |
PEG Ratio | 0.00 | −0.49 | 0.00 | |
Price/Book | 0.0x | 1.7x | 2.6x | |
Price / LTM Sales | 0.0x | 1.6x | 2.9x | |
Upside (Analyst Target) | 0.0% | 25.6% | 53.5% | |
Fair Value Upside | Unlock | 26.1% | 9.5% | Unlock |